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ABSTRACT
Background: Chronic obstructive pulmonary disease
(COPD) is widely underdiagnosed. A number of studies
have evaluated the accuracy of screening tests for
COPD, but their findings have not been formally
summarised. We therefore sought to determine and
compare the diagnostic accuracy of such screening
tests in primary care.
Methods: Systematic review and meta-analysis of the
diagnostic accuracy of screening tests for COPD
confirmed by spirometry in primary care. We searched
MEDLINE, EMBASE and other bibliographic databases
from 1997 to 2013 for diagnostic accuracy studies that
evaluated 1 or more index tests in primary care among
individuals aged ≥35 years with no prior diagnosis of
COPD. Bivariate meta-analysis of sensitivity and
specificity was performed where appropriate.
Methodological quality was assessed independently by
2 reviewers using the QUADAS-2 tool.
Results: 10 studies were included. 8 assessed
screening questionnaires (the COPD Diagnostic
Questionnaire (CDQ) was the most evaluated, n=4), 4
assessed handheld flow meters (eg, COPD-6) and 1
assessed their combination. Among ever smokers, the
CDQ (score threshold ≥19.5; n=4) had a pooled
sensitivity of 64.5% (95% CI 59.9% to 68.8%) and
specificity of 65.2% (52.9% to 75.8%), and handheld
flow meters (n=3) had a sensitivity of 79.9% (95% CI
74.2% to 84.7%) and specificity of 84.4% (68.9% to
93.0%). Inadequate blinding between index tests and
spirometry was the main risk of bias.
Conclusions: Handheld flow meters demonstrated
higher test accuracy than the CDQ for COPD screening
in primary care. The choice of alternative screening
tests within whole screening programmes should now
be fully evaluated.
PROSPERO registration number:
CRD42012002074.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is the third leading cause of death,1
ranks ninth for lost disability adjusted life
years,2 and is an important cause of healthcare
expenditure.3 Despite this, as much as 50–90%
of the disease burden remains undiagnosed.4
Patients often under-recognise the signiﬁcance
of respiratory symptoms,5 and clinicians fre-
quently miss opportunities to diagnose COPD
at primary care consultations.6 Early detection
may offer opportunities to reduce disease pro-
gression and improve quality of life, for
example, through smoking cessation interven-
tions7 and pulmonary rehabilitation.8 An ana-
lysis of the Health Survey for England
suggested that over three-quarters of symptom-
atic smokers identiﬁed with COPD through
targeted case ﬁnding could beneﬁt from
recommended therapies, which could poten-
tially prevent hospitalisations.9
There is now a policy drive to identify
undiagnosed COPD.10 11 However, a system-
atic review of population-based screening
with spirometry concluded that this should
not be recommended, partly because it esti-
mated that hundreds of smokers would need
to be screened to prevent a single COPD
exacerbation.12 Furthermore, without consid-
ering clinical symptoms, this approach could
identify individuals with airﬂow obstruction,
who would not meet the clinical criteria for
COPD according to current guidelines.11
Strengths and limitations of this study
▪ This is the first systematic review and
meta-analysis of the diagnostic accuracy of
screening tests for chronic obstructive pulmon-
ary disease (COPD) in primary care.
▪ Robust methods were used to identify, appraise
and summarise the available literature.
▪ There were few head-to-head comparisons of
screening tests.
▪ The definition of COPD used in the majority of
included studies was physiological, based on the
presence of airflow limitation, rather than clinical,
requiring the presence of relevant symptoms.
▪ Methodological limitations of included studies
included inadequate reporting of blinding of
operators performing and interpreting screening
and reference tests (spirometry) and reporting of
withdrawals and indeterminate results.
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Recently, efforts to identify undiagnosed COPD have
focused on the use of initial screening tests to identify
those at high risk, prior to diagnostic spirometry.13 14
Several approaches for initial screening have been evalu-
ated, but their ﬁndings have not been systematically
reviewed and quantitatively synthesised, and it is not yet
clear which test or combination is the most accurate.
Although one narrative review15 compared existing
symptom-based questionnaires, it did not include other
screening tests and needs updating.
We report a systematic review and meta-analysis of pub-
lished studies that summarises and compares the accur-
acy of screening tests for COPD in primary care.
METHODS
Protocol and registration
The protocol for this review was previously published16
and registered.17
Eligibility criteria
We sought diagnostic accuracy studies of any design that
evaluated one or more index tests, were conducted in
primary care (including general practices and commu-
nity pharmacies) and recruited individuals aged
≥35 years with no prior diagnosis of COPD. Index tests
included screening questionnaires, handheld ﬂow
meters (eg, Piko-6 or COPD-6), peak ﬂow meters, chest
radiography, and risk prediction models or decision
aids, either alone or in combination. We only included
studies that speciﬁed the target condition as COPD, and
used the presence of airﬂow obstruction, based on pre-
bronchodilator or postbronchodilator spirometry as the
reference standard (although postbronchodilator spir-
ometry was considered the ideal reference standard).
Outcomes
The primary outcome was identiﬁcation of COPD. The
main measures of test accuracy examined were sensitivity
and speciﬁcity.
Search strategy
We searched the following databases from March/April
2012 for the previous 15 years: MEDLINE, EMBASE,
CINAHL, Cochrane Central Register of Controlled Trials
and the Health Technology Database. We also per-
formed an updated search on MEDLINE and EMBASE
up to December 2013. Searches limited to the ﬁrst 100
articles were also performed on Google Scholar,
Turning Research into Practice, HTAi VORTAL and
DogPile, and selected conference abstracts for the previ-
ous 2 years. Search terms are listed in online supplemen-
tary table S1 and included Medical Subject Heading
terms and free-text synonyms for COPD, screening tests
and measures of test accuracy, with no language
restrictions.
Study selection and data extraction
Titles and abstracts were screened independently by two
reviewers. Relevant full-text articles were independently
assessed for eligibility by two reviewers and disagree-
ments resolved through discussion. Prespeciﬁed data
were extracted from full-text articles by one reviewer and
veriﬁed by a second. We extracted the number of true
positives, false positives, true negatives and false nega-
tives for construction of two-by-two contingency tables.
Where these data were not provided, reported measures
of test accuracy were used to derive these values.
Risk of bias assessment
Included studies were assessed independently by two
reviewers for risk of methodological bias and applicabil-
ity concerns against criteria from the QUADAS-2 tool.18
Online supplementary table S2 shows how this was
adapted for the review. Disagreements were resolved
through discussion.
Statistical analysis
Forest plots of sensitivity and speciﬁcity were constructed
using Review Manager (RevMan) V.5.2 (Copenhagen:
The Nordic Cochrane Centre, The Cochrane
Collaboration, 2012). These plots were used to visually
explore between-study variation in the diagnostic accur-
acy of each test. We also explored differences in popula-
tion screened, screening test, diagnostic criteria and
study design.
Where there was sufﬁcient clinical and methodo-
logical homogeneity, we used the xtmelogit command in
Stata V.13.1 (Stata-Corp, College Station, Texas, USA) to
ﬁt the bivariate model19 20 to derive summary estimates
of sensitivity and speciﬁcity and their 95% CIs. If there
were fewer than four studies, we simpliﬁed the bivariate
model to two univariate random effects logistic regres-
sion models for sensitivity and speciﬁcity by assuming no
correlation between both measures.21 We used two
approaches to compare the diagnostic accuracy of the
screening tests. First, we used all relevant studies that
evaluated one or more tests, and second we restricted
the analysis to studies that made direct (head-to-head)
comparisons. Where meta-analysis was possible, tests
were compared by adding a covariate for test type to the
bivariate model to assess whether average sensitivity
and/or speciﬁcity differed between the tests. To assess
the statistical signiﬁcance of differences in sensitivity and
speciﬁcity between tests, we compared the ﬁt of alterna-
tive models (effect of adding or removing covariate
terms from the model) by using likelihood ratio tests.
Positive and negative predictive values (PPV and NPV)
were estimated from the sensitivity and speciﬁcity of
each test, assuming a prevalence of undiagnosed COPD
of 5.5%9 in a hypothetical population of 1000 patients
aged ≥40 years. We estimated the number-needed-to-
screen to identify one individual with COPD as the total
number screened divided by the number of true
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positives, and the number of diagnostic assessments
needed as the reciprocal of the PPV.
RESULTS
Study selection
The stages of study selection are shown in ﬁgure 1. After
excluding duplicates, our search yielded 2605 records.
From these, full-text articles were retrieved for 266
studies. Ten studies met the inclusion criteria, and ﬁve
were suitable for meta-analysis (since these were sufﬁ-
ciently similar with respect to the included population,
screening tests and deﬁnition of COPD). Figure 1 lists
the reasons for excluding articles, the most common of
which was the inclusion of patients with previously
known COPD.
Study characteristics
Characteristics of included studies are summarised in
tables 1 and 2 (see online supplementary tables S3–5 for
details of each study). All were cross-sectional test accur-
acy studies, of which two used a paired design to
compare two screening tests (screening questionnaires
and handheld ﬂow meters).22 23 Nine studies were multi-
centre and all were based in general practices.
Recruitment and population selection
Four studies opportunistically recruited patients rou-
tinely attending primary care, three actively recruited
participants through postal invitations or local advertise-
ments, two used a combination of both strategies and
one study did not report the method of recruitment.24
All studies speciﬁed age in the inclusion criteria with
most requiring participants to be over 40 years. Seven
studies also required a positive smoking history, but only
one required participants to report respiratory symptoms
as part of the entry criteria.13 The main exclusion criter-
ion was an established history of lung disease.
Index and reference tests
All studies ﬁrst applied one or more index tests to the
eligible population and then performed the reference
test (spirometry) on either all (n=8 studies) or a
random sample25 26 (n=2) of participants. Index tests
included screening questions or questionnaires (n=8)
and handheld ﬂow meters (n=4). One study also
assessed the combined accuracy of using a screening
questionnaire sequentially with a handheld ﬂow meter.22
No studies evaluating other screening tests met the
inclusion criteria.
Reference standard
Prebronchodilator and postbronchodilator spirometry
was the reference standard in two25 27 and eight studies,
respectively (tables 1 and 2). Most studies sufﬁciently
described spirometry and quality control procedures.
Spirometry was performed by trained technicians (n=4),
Figure 1 Study selection
(COPD, chronic obstructive
pulmonary disease).
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general practitioners (GPs; n=1), pulmonary physicians
(n=1) and nurses (n=2), while quality control was
usually performed by a respiratory specialist or physiolo-
gist who reviewed spirometry results.
Methodological quality
Most studies gave a clear description of participants,
index and reference tests, and diagnostic criteria (see
online supplementary figure S1 and table S6). However,
there was often under-reporting of withdrawals (n=4),
participant ﬂow diagrams (n=5) and uninterpretable
spirometry tests (n=5). The main risk of bias arose from
inadequate blinding between index and reference tests
(n=7; ﬁgures 2 and 3). There was also potential for bias
in the ﬂow and timing domain (n=5), where the
number of participants undergoing index and reference
tests was unclear, and where signiﬁcant numbers of par-
ticipants were excluded from the analysis.
Screening questionnaires
Altogether four screening questionnaires were evaluated
on a total of 9472 participants in eight studies (table 1),
of which the COPD Diagnostic Questionnaire (CDQ),28
also referred to as the International Primary Airways
Group (IPAG) Questionnaire,22 was the most widely vali-
dated (n=4).13 22 23 28 All instruments included ques-
tions related to the presence of respiratory symptoms
(usually cough, dyspnoea and wheeze). Other items
included in some, but not all questionnaires related to
smoking history, allergies, age, body mass index (BMI)
Table 1 Characteristics of studies evaluating screening questionnaires (8 studies)13 22–25 27 28 38
Characteristic
Range/number
of studies
Study designs Cross-sectional test accuracy 8
Participants 237–3158
Mean age (years) 52.3–65.3
Male (%) 38.1–69.0
Required smoking status Only current/ex-smokers 5
Included never-smokers 3
Required respiratory symptoms 1
Setting General practice(s) 8
Number of centres 1–36
Multicentre 7
Single centre 1
Recruitment strategy Active 2
Opportunistic 3
Active and opportunistic 2
Not reported 1
Questionnaires COPD Diagnostic Questionnaire* 4
Lung Function Questionnaire 2
Not named 2
Common items
Age 7
Smoking status 7
Respiratory symptoms 8
Allergies 5
Reference test—spirometry
Post-BD 6
Definition of airflow obstruction Post-BD FEV1/FVC <0.7 7
Other† 1
Included symptoms in definition of COPD 1
Spirometry quality control Yes 8
Range of results
Sensitivity 57–93%
Specificity 24–80%
Severity of new COPD cases ≥80% 11–39%
(FEV1% predicted)‡ 50–80% 43–61%
<50% 10–37%
*Also referred to as the Respiratory Health Screening Questionnaire and the IPAG questionnaire.
†Pre-BD FEV1/FVC <88.5% predicted for men and FEV1/FVC <89.3% for women.
‡Based on five studies.
BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IPAG,
International Primary Airways Group.
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and physical functioning. Overall, participants were
similar in age (range 52.3–65.3 years) but varied by sex
(range 38–69% male).
COPD Diagnostic Questionnaire
Four studies13 22 23 28 that evaluated the CDQ in ever
smokers were included in a meta-analysis. Using a score
threshold of ≥19.5, the pooled sensitivity was 64.5%
(95% CI 59.9% to 68.8%) and speciﬁcity 65.2% (95%
CI 52.9% to 75.8%; table 3). With a prevalence of
undiagnosed COPD of 5.5%, this gave a PPV of 9.7%
(95% CI 6.9% to 14.2%), NPV of 96.9% (95% CI 95.8%
to 97.7%), and would require 29 individuals (95% CI 27
to 31) to complete the CDQ and 11 (95% CI 7 to 15) to
undergo a diagnostic assessment to identify one individ-
ual with COPD. At a lower score threshold of ≥16.5, the
pooled sensitivity was higher but the speciﬁcity lower,
requiring 21 individuals (95% CI 20 to 22) to complete
the questionnaire and 13 (95% CI 11 to 16) to undergo
a diagnostic assessment for each new diagnosis.
All other questionnaires
There was considerable between-study heterogeneity in
the design of other screening questionnaires, which pre-
cluded their meta-analysis. In these four studies, sensitiv-
ities ranged from 57% to 88% and speciﬁcities from
25% to 80% (ﬁgure 4).
Handheld flow meters
The test accuracy of handheld ﬂow meters was evaluated
in 1400 participants across four studies (table 2).14 22 23 26
Participants were similar in age (range 52–65.3 years) but
varied by sex (range 43–99.7% male). Only one study
included never-smokers and stratiﬁed the results by
smoking status.22
Table 2 Characteristics of studies evaluating handheld flow meters (4 studies)14 22 23 26
Characteristic Range/number of studies
Study designs Cross-sectional test accuracy study 4
Participants 305–2464
Mean age (years) 52.0–65.3
Male (%) 43.3–99.7
Required smoking status Only current/ex-smokers 3
Included never-smokers 1
Required respiratory symptoms 0
Setting General practice(s) 4
Number of centres 4–25
Multicentre 4
Recruitment strategy Active 1
Opportunistic 2
Active and opportunistic 1
Handheld flow meter
Device Piko-6 3
COPD-6 1
Operator Nurse 2
GP 1
Not reported 1
Use of BD Pre-BD 3
Post-BD 1
Test threshold FEV1/FEV6< 0.70–0.75
Reference test—spirometry
Post-BD 4
Definition of airflow obstruction Post-BD FEV1/FVC <0.7 4
Included symptoms in definition of COPD 0
Spirometry quality control Yes 2
No 1
Unclear 1
Range of results
Sensitivity 79–86%
Specificity 71–99%
Severity of new COPD cases ≥80% 35–48%
(FEV1% predicted)
3 50–80% 48–65%
<50% 0–16%
BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GP,
general practitioner.
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Handheld ﬂow meters differ from diagnostic spirom-
eters in that they are limited to measuring the forced
expiratory volume in 1 and 6 s (FEV1 and FEV6, respect-
ively), are usually performed with three blows and are
cheaper and quicker to administer. They were used
without a bronchodilator in three studies14 23 26 and
were supervised by either trained nurses or GPs. A
narrow range of thresholds were used to denote a posi-
tive test ranging from FEV1/FEV6 <0.7 to 0.75.
Their sensitivity ranged from 79% to 86% and speciﬁcity
from 71% to 99% (ﬁgure 4). Three studies14 22 23 enrol-
ling ever smokers were similar enough to be included in a
meta-analysis. The pooled sensitivity was 79.9% (95% CI
74.2% to 84.7%) and speciﬁcity was 84.4% (95% CI 68.9%
to 93.0%). Using the same assumptions, this would
require 23 individuals (95% CI 22 to 24) to be screened
and 5 (95% CI 3 to 9) to undergo a diagnostic assessment
to identify 1 individual with COPD (table 3).
Combination of tests
In the single study that reported the combined accuracy
of a screening questionnaire (CDQ) with a handheld
ﬂow meter, the sensitivity was 74% (95% CI 64% to
83%) and speciﬁcity was 97% (95% CI 95% to 98%).22
This would reduce the need for diagnostic assessment to
two individuals (95% CI 2 to 3) to identify one with
COPD (table 3 and ﬁgure 5).
Comparison of test accuracy
In the ﬁrst comparative analysis, based on an indirect com-
parison in ever smokers, there was evidence from the likeli-
hood ratio tests that the CDQ at a score threshold of ≥19.5
had a lower sensitivity (p=0.003) but no difference in spe-
ciﬁcity (p=0.09) compared with handheld ﬂow meters. In
the second analysis at the lower score threshold of ≥16.5
(or 17), there was evidence to suggest a higher sensitivity
(p=0.03) but a much lower speciﬁcity (p=0.01) than hand-
held ﬂow meters. Two studies directly compared handheld
ﬂow meters and the CDQ22 23 and their ﬁndings were con-
sistent with the results of the indirect comparison.
Furthermore, Frith et al23 also reported both higher sensi-
tivity and speciﬁcity of handheld ﬂow meters compared
with the CDQ at the score threshold of ≥19.5.
DISCUSSION
Summary of evidence
This review incorporated evidence on the test accuracy
of questionnaires and handheld ﬂow meters for COPD
screening in primary care. The CDQ developed by Price
et al28 was the most widely validated of the four screen-
ing questionnaires included. However, use of handheld
ﬂow meters under the supervision of trained health pro-
fessionals was signiﬁcantly more accurate than the CDQ
for discriminating between ever smokers with and
without airway obstruction, and a combination of both
instruments may improve the accuracy still further,
potentially reducing the number of diagnostic assess-
ments required.22 Studies evaluating the CDQ and hand-
held ﬂow meters had generally few methodological
biases, the main being insufﬁcient clarity on blinding
between index and reference tests.
Unfortunately, only one study by Kotz et al13 consid-
ered the accuracy of a screening test (handheld ﬂow
meter) for identifying airﬂow obstruction in symptom-
atic patients, which is closer to identifying clinical
COPD. The remainder evaluated the accuracy for identi-
fying airﬂow obstruction without explicitly considering
the presence of symptoms. Nevertheless, the results are
still likely to apply since we observed that the test accur-
acy reported by Kotz et al13 was very similar to that
reported by studies that did not explicitly consider
respiratory symptoms.
Figure 2 Risk of bias and
applicability concerns graph:
review authors’ judgements about
each domain presented as
percentages across included
studies.
Figure 3 Risk of bias and applicability concerns summary:
review authors’ judgements about each domain for each
included study.
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Relationship to other studies
The US Preventive Services Task Force (USPSTF) and the
UK National Screening Committee recommended against
routine screening for COPD partly due to concerns
about efﬁciency and costs.12 29 However, the USPSTF evi-
dence review did not consider the use of screening tests
such as questionnaires and handheld ﬂow meters that
may help triage high-risk patients for diagnostic assess-
ment as suggested by our ﬁndings. Screening was recom-
mended against on the basis that it would lead largely to
the diagnosis of mild-to-moderate disease, for which
there is limited evidence on effective interventions.12 30
However, a signiﬁcant proportion of new diagnoses of
COPD in our included studies had moderate-to-severe
airﬂow obstruction (48.9%13 to 88.5%27 with an FEV1
<80% predicted)—these patients are likely to beneﬁt
from established therapies for COPD.8
In 2005, van Schayck et al15 compared symptom-based
questions for identifying COPD and validated their
accuracy using data from the National Health and
Nutrition Examination Survey (NHANES) III. Age, BMI,
smoking status, smoking intensity, self-reported asthma,
chronic bronchitis or emphysema, and chronic cough or
phlegm represented the optimal combination of vari-
ables for identifying individuals with airﬂow obstruction,
having a sensitivity of 71% and speciﬁcity of 67%. Many
of these risk factors have been incorporated in screening
questionnaires evaluated in our review and their com-
bined accuracy appears to be lower than handheld ﬂow
meters. Furthermore, a meta-analysis of studies evaluat-
ing the accuracy of FEV1/FEV6 measured by standard
diagnostic spirometry for detecting airﬂow obstruction
showed it has a sensitivity of 0.89 (95% CI 0.83 to 0.93)
and speciﬁcity of 0.98 (95% 0.95 to 0.99).31 While the
accuracy of handheld ﬂow meters (which measure
FEV1/FEV6) appears to be lower than this, the ﬁndings
from the current review suggest that they are still sufﬁ-
ciently accurate to screen for airﬂow limitation.
Finally, we identiﬁed two recent relevant studies that
fell outside the time window of our literature search.
The ﬁrst invited ever smokers aged 40–85 years from 36
general practices to complete the CDQ and perform
spirometry.32 The CDQ showed a sensitivity and speciﬁ-
city of 63.0% and 70.1%, respectively, when using a
score threshold of ≥19.5 and 79.7% and 46.8% using a
cut-point of ≥16.5. The second study evaluated the NPV
of handheld ﬂow meters among a small sample (n=54)
of ex-smokers aged ≥50 years who had been referred for
diagnostic spirometry by their GP.33 The NPV was esti-
mated at 94.4% (95% CI 86.4% to 98.5%) when using
the ﬁxed ratio of FEV1/forced vital capacity (FVC) <0.7
to deﬁne airﬂow obstruction. Both ﬁndings are in
keeping with our meta-analyses.
Strengths and weaknesses of the review
Strengths of this review include the methods used to
identify and appraise the available literature. Other than
the limitation of the case deﬁnition discussed above, the
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weaknesses result mainly from the methodological lim-
itations of included studies, particularly with respect to
inadequate reporting of withdrawals and indeterminate
results and blinding of operators performing and inter-
preting index and reference tests. This may have
resulted in overestimation of test accuracy since positive
index tests could plausibly inﬂuence performance and
interpretation of reference spirometry. There was also a
lack of head-to-head comparisons with only two studies
evaluating more than one screening test.22 23 Indirect
comparisons are potentially biased because of differ-
ences in population and study characteristics.
The criteria for airﬂow obstruction used in the
included studies is also a point of contention given that
using a ﬁxed cut-off of FEV1/FVC <0.7 may lead to over-
diagnosis of the elderly.34 35 Future studies should there-
fore consider using a deﬁnition that accounts for age,
sex and ethnicity biases, ideally using an FEV1/FVC ratio
below the lower limit of normal36 and using the ﬁxed
ratio for sensitivity analyses.
Finally, the included studies did not report acceptabil-
ity and uptake of screening tests, which are all important
for evaluating their overall effectiveness. This review can
therefore only be used to comment on test accuracy and
not on comparative clinical and cost-effectiveness in
routine practice, which ideally should be evaluated
through head-to-head trials.
Implications for research and practice
Our ﬁndings suggest that handheld ﬂow meters are
likely to be more accurate than questionnaires for
COPD screening in primary care. However, we also high-
light several key limitations of previous studies. Future
studies should provide clear descriptions of withdrawals,
including participant ﬂow diagrams, ensure that spirom-
etry is performed without prior knowledge of index
tests, and that indeterminate results, particularly with
respect to spirometry, are reported. Future studies
should also aim to recruit participants with no prior
diagnosis of COPD (thus reducing the risk of spectrum
bias37) and use a clinical case deﬁnition, rather than just
airway obstruction, in order to increase generalisability
to real-life practice. More studies are needed to evaluate
the accuracy and effectiveness of combining screening
tests and to assess their cost-effectiveness. Finally, it
remains unclear whether early detection of COPD sig-
niﬁcantly improves clinical outcomes and quality of life.
This should ﬁrst be demonstrated in prospective studies
before ﬁrm recommendations are made.
CONCLUSIONS
Handheld ﬂow meters used under the supervision of a
trained health professional are more accurate than the
CDQ for detecting spirometry-conﬁrmed COPD in
Figure 4 Forest plot of sensitivity and specificity of each screening test. (1) Binary response questionnaire, (2) multiple
response questionnaire. COPD, chronic obstructive pulmonary disease; TP, true positive; FP, false positive; FN, false negative;
TN, true negative.
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primary care. Limited evidence suggests that combining
both tests may potentially improve test accuracy. Future
studies should employ a case deﬁnition of COPD that
aligns with current recommendations and include
head-to-head comparisons.
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